Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Other Non-Current Assets: 2022-2024

Historic Other Non-Current Assets for Taysha Gene Therapies (TSHA) over the last 3 years, with Dec 2024 value amounting to $2.2 million.

  • Taysha Gene Therapies' Other Non-Current Assets changed negligibly% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $2.2 million for FY2024, which is 17.27% down from last year.
  • According to the latest figures from FY2024, Taysha Gene Therapies' Other Non-Current Assets is $2.2 million, which was down 17.27% from $2.6 million recorded in FY2023.
  • Taysha Gene Therapies' Other Non-Current Assets' 5-year high stood at $2.6 million during FY2022, with a 5-year trough of $2.2 million in FY2024.
  • Moreover, its 3-year median value for Other Non-Current Assets was $2.6 million (2023), whereas its average is $2.5 million.
  • Data for Taysha Gene Therapies' Other Non-Current Assets shows a maximum YoY dropped of 17.27% (in 2024) over the last 5 years.
  • Taysha Gene Therapies' Other Non-Current Assets (Yearly) stood at $2.6 million in 2022, then dropped by 1.40% to $2.6 million in 2023, then decreased by 17.27% to $2.2 million in 2024.